Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer

Atsushi Naito; Tsunekazu Mizushima; Hiroshi Takeyama; Daisuke Sakai; Mamoru Uemura; Toshihiro Kudo; Junichi Nishimura; Shinichiro Shinzaki; Taishi Hata; Taro Sato; Ichiro Takemasa; Kiyokazu Nakajima; Hideki Iijima; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori

Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer

Atsushi Naito, Tsunekazu Mizushima, Hiroshi Takeyama, Daisuke Sakai, Mamoru Uemura, Toshihiro Kudo, Junichi Nishimura, Shinichiro Shinzaki, Taishi Hata, Taro Sato, Ichiro Takemasa, Kiyokazu Nakajima, Hideki Iijima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Long-standing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), is a known risk factor for gastrointestinal (GI) cancer, especially colorectal cancer (CRC). However, the feasibility of chemotherapy for IBD-related GI cancer is not well understood in terms of efficacy and adverse events, because there are fewer GI cancer patients with IBD than without IBD.

METHODOLOGY: We retrospectively analyzed the medical records of eight IBD patients (CD = 5 and UC = 3) who received chemotherapy for IBD-related GI cancer between April 2003 and March 2013.

RESULTS: The most common gastrointestinal adverse event was diarrhea (75%); 38% of patients experienced grade 3 diarrhea. Moreover, all grade 3 diarrhea occurred in patients with CD. The most common hematologic adverse events were anemia (75%), leukopenia (38%), and neutropenia (30%); 25% of patients experienced grade 3 neutropenia. The other severe adverse events were grade 3 AST and ALT elevation (13%).

CONCLUSIONS: In this study, the incidence of grade 3 diarrhea was higher in patients with CD. The length and dysfunction of the small intestine is the most likely reason that diarrhea occurred more frequently in patients with CD.

Original language	English
Pages (from-to)	942-946
Number of pages	5
Journal	Hepato-gastroenterology
Volume	61
Issue number	132
Publication status	Published - Jun 1 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c057d1756c194ba9bb30e56d0da90474,

title = "Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer",

abstract = "BACKGROUND/AIMS: Long-standing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), is a known risk factor for gastrointestinal (GI) cancer, especially colorectal cancer (CRC). However, the feasibility of chemotherapy for IBD-related GI cancer is not well understood in terms of efficacy and adverse events, because there are fewer GI cancer patients with IBD than without IBD.METHODOLOGY: We retrospectively analyzed the medical records of eight IBD patients (CD = 5 and UC = 3) who received chemotherapy for IBD-related GI cancer between April 2003 and March 2013.RESULTS: The most common gastrointestinal adverse event was diarrhea (75%); 38% of patients experienced grade 3 diarrhea. Moreover, all grade 3 diarrhea occurred in patients with CD. The most common hematologic adverse events were anemia (75%), leukopenia (38%), and neutropenia (30%); 25% of patients experienced grade 3 neutropenia. The other severe adverse events were grade 3 AST and ALT elevation (13%).CONCLUSIONS: In this study, the incidence of grade 3 diarrhea was higher in patients with CD. The length and dysfunction of the small intestine is the most likely reason that diarrhea occurred more frequently in patients with CD.",

author = "Atsushi Naito and Tsunekazu Mizushima and Hiroshi Takeyama and Daisuke Sakai and Mamoru Uemura and Toshihiro Kudo and Junichi Nishimura and Shinichiro Shinzaki and Taishi Hata and Taro Sato and Ichiro Takemasa and Kiyokazu Nakajima and Hideki Iijima and Hirofumi Yamamoto and Yuichiro Doki and Masaki Mori",

year = "2014",

month = jun,

day = "1",

language = "English",

volume = "61",

pages = "942--946",

journal = "Hepato-gastroenterology",

issn = "0172-6390",

publisher = "H.G.E. Update Medical Publishing Ltd.",

number = "132",

}

TY - JOUR

T1 - Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer

AU - Naito, Atsushi

AU - Mizushima, Tsunekazu

AU - Takeyama, Hiroshi

AU - Sakai, Daisuke

AU - Uemura, Mamoru

AU - Kudo, Toshihiro

AU - Nishimura, Junichi

AU - Shinzaki, Shinichiro

AU - Hata, Taishi

AU - Sato, Taro

AU - Takemasa, Ichiro

AU - Nakajima, Kiyokazu

AU - Iijima, Hideki

AU - Yamamoto, Hirofumi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2014/6/1

Y1 - 2014/6/1

N2 - BACKGROUND/AIMS: Long-standing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), is a known risk factor for gastrointestinal (GI) cancer, especially colorectal cancer (CRC). However, the feasibility of chemotherapy for IBD-related GI cancer is not well understood in terms of efficacy and adverse events, because there are fewer GI cancer patients with IBD than without IBD.METHODOLOGY: We retrospectively analyzed the medical records of eight IBD patients (CD = 5 and UC = 3) who received chemotherapy for IBD-related GI cancer between April 2003 and March 2013.RESULTS: The most common gastrointestinal adverse event was diarrhea (75%); 38% of patients experienced grade 3 diarrhea. Moreover, all grade 3 diarrhea occurred in patients with CD. The most common hematologic adverse events were anemia (75%), leukopenia (38%), and neutropenia (30%); 25% of patients experienced grade 3 neutropenia. The other severe adverse events were grade 3 AST and ALT elevation (13%).CONCLUSIONS: In this study, the incidence of grade 3 diarrhea was higher in patients with CD. The length and dysfunction of the small intestine is the most likely reason that diarrhea occurred more frequently in patients with CD.

AB - BACKGROUND/AIMS: Long-standing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), is a known risk factor for gastrointestinal (GI) cancer, especially colorectal cancer (CRC). However, the feasibility of chemotherapy for IBD-related GI cancer is not well understood in terms of efficacy and adverse events, because there are fewer GI cancer patients with IBD than without IBD.METHODOLOGY: We retrospectively analyzed the medical records of eight IBD patients (CD = 5 and UC = 3) who received chemotherapy for IBD-related GI cancer between April 2003 and March 2013.RESULTS: The most common gastrointestinal adverse event was diarrhea (75%); 38% of patients experienced grade 3 diarrhea. Moreover, all grade 3 diarrhea occurred in patients with CD. The most common hematologic adverse events were anemia (75%), leukopenia (38%), and neutropenia (30%); 25% of patients experienced grade 3 neutropenia. The other severe adverse events were grade 3 AST and ALT elevation (13%).CONCLUSIONS: In this study, the incidence of grade 3 diarrhea was higher in patients with CD. The length and dysfunction of the small intestine is the most likely reason that diarrhea occurred more frequently in patients with CD.

UR - http://www.scopus.com/inward/record.url?scp=84938932827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938932827&partnerID=8YFLogxK

M3 - Article

C2 - 26158146

AN - SCOPUS:84938932827

SN - 0172-6390

VL - 61

SP - 942

EP - 946

JO - Hepato-gastroenterology

JF - Hepato-gastroenterology

IS - 132

ER -

Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this